Halozyme Therapeutics, Inc.

H. Michael Shepard, Ph.D., has joined Halozyme Therapeutics as vice president, discovery research. Dr. Shepard is a recipient of numerous biotechnology patents and scientific awards for his contributions to the development of innovative therapies. He has more than 25 years of experience in the biotechnology industry. At Genentech, Dr. Shepard led the team that discovered the breast cancer drug, Herceptin, which was designed to attack HER2 positive breast cancers. In 2007, Dr. Shepard shared the Warren Alpert Prize from Harvard Medical School in recognition of this achievement.

Dr. Shepard also built successful programs at various biotechnology companies in areas including antibiotics, cancer gene therapy and receptor fusion proteins. He served as chief scientific officer of Canji, Inc. and, most recently, founder and president of Receptor BioLogix, Inc.

“We are delighted to have Dr. Shepard’s discovery research leadership at Halozyme,” said Gregory Frost, Ph.D., Halozyme’s chief scientific officer. “Mike’s ability to translate his broad scientific understanding into innovative biologics complements the research and development team at Halozyme as we build a world class biopharmaceutical organization.”